We are live on ! Find out more
ACM

Asymmetry Capital Management Portfolio holdings

AUM $188M
1-Year Est. Return 44.72%
This Fund
S&P 500
This Quarter Est. Return
+14.66%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$86.2M
AUM Growth
+$1.9M
Cap. Flow
-$5.96M
Cap. Flow %
-6.91%
Top 10 Hldgs %
59.3%
Holding
39
New
11
Increased
6
Reduced
15
Closed
7

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$4.06M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$2.93M
3
NITE
Nightstar Therapeutics plc American Depositary Shares
NITE
+$2.81M
4
NVTA
Invitae Corporation
NVTA
+$2.79M
5
HMSY
HMS Holdings Corp.
HMSY
+$2.64M

Top Sells

Rank Stock Value
1
NVRO
NEVRO CORP.
NVRO
+$4.2M
2
MDT icon
Medtronic
MDT
+$4.05M
3
GILD icon
Gilead Sciences
GILD
+$4.05M
4
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$3.58M
5
PTCT icon
PTC Therapeutics
PTCT
+$3.38M

Sector Composition

Rank Sector Weight
1 Healthcare 90.93%
2 Industrials 3.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTCT icon
1
PTC Therapeutics
PTCT
$6.47B
$7.11M 8.25%
355,456
-172,659
-33% -$3.38M
CNC icon
2
Centene
CNC
$32.5B
$6.76M 7.84%
139,668
+27,964
+25% +$1.2M
INSM icon
3
Insmed
INSM
$23.2B
$6.66M 7.72%
+213,376
New +$4.06M
JAZZ icon
4
Jazz Pharmaceuticals
JAZZ
$15.3B
$6.16M 7.14%
42,092
+10,753
+34% +$1.63M
UNH icon
5
UnitedHealth
UNH
$383B
$4.91M 5.69%
25,062
-856
-3% -$165K
SRPT icon
6
Sarepta Therapeutics
SRPT
$1.78B
$4.77M 5.53%
105,066
-53,744
-34% -$2.15M
BIO icon
7
Bio-Rad Laboratories Class A
BIO
$8.08B
$4.5M 5.22%
20,242
-127
-0.6% -$28.6K
DGX icon
8
Quest Diagnostics
DGX
$23B
$3.58M 4.15%
38,220
+7,466
+24% +$793K
ACHC icon
9
Acadia Healthcare
ACHC
$3.17B
$3.48M 4.04%
72,889
-9,805
-12% -$478K
FOLD
10
DELISTED
Amicus Therapeutics
FOLD
$3.21M 3.73%
213,059
-188,850
-47% -$2.5M
NBIX icon
11
Neurocrine Biosciences
NBIX
$17.4B
$3.16M 3.66%
51,497
+17,467
+51% +$922K
NTRA icon
12
Natera
NTRA
$37.6B
$3.06M 3.54%
237,118
+173,307
+272% +$1.92M
IONS icon
13
Ionis Pharmaceuticals
IONS
$8.75B
$2.84M 3.29%
+55,965
New +$2.93M
HMSY
14
DELISTED
HMS Holdings Corp.
HMSY
$2.82M 3.27%
+141,906
New +$2.64M
NVTA
15
DELISTED
Invitae Corporation
NVTA
$2.75M 3.19%
+293,819
New +$2.79M
TCMD icon
16
Tactile Systems Technology
TCMD
$640M
$2.57M 2.98%
82,976
+22,056
+36% +$698K
NITE
17
DELISTED
Nightstar Therapeutics plc American Depositary Shares
NITE
$2.5M 2.89%
+130,007
New +$2.81M
DRRX
18
DELISTED
DURECT Corp
DRRX
$1.57M 1.82%
88,820
-16,027
-15% -$269K
JUNO
19
DELISTED
Juno Therapeutics, Inc.
JUNO
$1.38M 1.6%
+30,760
New +$1.05M
INGN icon
20
Inogen
INGN
$173M
$1.34M 1.56%
14,113
-6,629
-32% -$639K
ALDR
21
DELISTED
Alder Biopharmaceuticals
ALDR
$1.29M 1.49%
105,228
-61,524
-37% -$641K
MDT icon
22
Medtronic
MDT
$107B
$1.27M 1.47%
16,295
-48,741
-75% -$4.05M
CLVS
23
DELISTED
Clovis Oncology, Inc.
CLVS
$1.15M 1.34%
14,008
-18,377
-57% -$1.46M
NVRO
24
DELISTED
NEVRO CORP.
NVRO
$1.07M 1.24%
11,804
-49,089
-81% -$4.2M
TVTY
25
DELISTED
Tivity Health, Inc. Common Stock
TVTY
$1.05M 1.21%
+25,654
New +$994K
1
2

Similar funds

FAC
Forrestal Agricultural Corporation Princeton, New Jersey $183M AUM
SWM
Strategic Wealth Management Kirkland, Washington $202M AUM 9.35% 1-Year Est. Return
MC
MRJ Capital New York $173M AUM 31.99% 1-Year Est. Return
KM
Kylin Management New York $173M AUM 39.51% 1-Year Est. Return
TI
Truehand Inc Strafford, New Hampshire $171M AUM 25.9% 1-Year Est. Return
GC
Grace Capital Quincy, Massachusetts $168M AUM 21.6% 1-Year Est. Return
REMS
Real Estate Management Services $167M AUM 37.69% 1-Year Est. Return
NM
Nokota Management New York $165M AUM

Asymmetry Capital Management's Q3 2017 Portfolio in Review

As of Q3 2017, Asymmetry Capital Management held 39 positions worth $86.2M, up 2.3% from $84.3M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Asymmetry Capital Management withdrew a net $5.96M in Q3 2017, closing 7 positions and reducing 15 holdings. Its most notable exit was Gilead Sciences, an estimated $4.05M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 98% a quarter earlier, followed by Industrials.

Against the trend, Asymmetry Capital Management opened a new position in Insmed worth $6.66M.

  • Asymmetry Capital Management's largest Q3 2017 buy was Insmed: 213,376 shares worth $6.66M.
  • Asymmetry Capital Management added most to Natera in Q3 2017, an estimated $1.92M increase.
  • Asymmetry Capital Management's biggest Q3 2017 reduction was NEVRO CORP., cutting an estimated $4.2M.
  • Asymmetry Capital Management fully exited Gilead Sciences in Q3 2017, selling an estimated $4.05M.
  • Asymmetry Capital Management's ten largest holdings make up 59% of its $86.2M portfolio in Q3 2017.
  • Asymmetry Capital Management opened 11 new positions and closed 7 in Q3 2017.
  • Asymmetry Capital Management's portfolio value rose 2.3% quarter-over-quarter to $86.2M.

Based on Asymmetry Capital Management's 13F filing for Q3 2017, filed 3 Nov 2017.